Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

Table 4 Multivariable logistic regression analysis to predict classification in pRLDA compared to pMDA group

pRLDA classification (vs pMDA)	Univariable analysis			Multivariable analysis^†
pRLDA classification (vs pMDA)	OR	95% CI	p value	OR	95% CI	p value
Gender female (vs male)	0.31	0.18 to 0.52	p < 0.001*	0.38	0.17 to 0.84	p = 0.017*
Age (per year)	0.97	0.95 to 0.98	p < 0.001*	0.98	0.96 to 1.02	p = 0.26
Disease duration (per year)	1.01	0.98 to 1.03	p = 0.65	0.99	0.95 to 1.03	p = 0.68
Previous csDMARDs, count < 2	1.56	0.91 to 2.67	p = 0.11	1.11	0.49 to 2.5	p = 0.8
Anti-TNF baseline	5.54	1.3 to 23.57	p = 0.02*	2.9	0.51 to 16.55	p = 0.23
DAS28 baseline (per unit)	0.27	0.2 to 0.38	p < 0.001*	0.45	0.29 to 0.7	p < 0.001*
HAQ baseline (per unit)	0.21	0.11 to 0.4	p < 0.001*	0.53	0.2 to 1.38	p = 0.19
DAS28 1st semester (per unit)	0.17	0.11 to 0.25	p < 0.001*	0.19	0.12 to 0.29	p < 0.001*
ΔHAQ 1st semester < − 0.22	0.65	0.37 to 1.15	p = 0.14	0.38	0.16 to 0.91	p = 0.029*

pRLDA persistent remission/low disease activity group, pMDA persistent moderate disease activity group, cDMARDs conventional synthetic disease-modifying antirheumatic drugs, 1st semester therapy months 3–9, HAQ Health Assessment Questionnaire, ΔHAQ HAQ difference 1st semester’s average from baseline, ACC accuracy, TPR sensitivity, TNR specificity, AUC area under receiver-operating-characteristic curve
^†Multivariable analysis efficiency (10-fold cross-validation): ACC = 88.3%, TPR = 68%, TNR = 95%, AUC = 91%
*Below significance threshold 0.05

ISSN: 1478-6362